When to Avoid GoodRx: Specific Patient Profiles That Should Not Rely on This Discount Program

Is GoodRx Legit?

GoodRx is a legitimate, FTC-registered discount facilitator, not a fraudulent service. LegitScript classifies it as a certified pharmacy program facilitator, and it has Better Business Bureau accreditation. Legitimacy, however, is not the same as suitability. The program has real regulatory and financial constraints that make it actively harmful for certain patient groups.

What GoodRx Actually Is

GoodRx operates as a pharmacy benefit manager (PBM) negotiator, not an insurer. It contracts with pharmacy networks to offer pre-negotiated cash prices. The patient pays that cash price directly, with no claim submitted to insurance. This model works well for uninsured patients buying cheap generics, but it breaks down the moment a patient has active coverage or needs a high-cost medication.

The FTC and several state attorneys general have scrutinized the PBM industry broadly. The FTC's 2023 interim report on PBM practices noted that opaque pricing and spread pricing harm consumers and payers alike (FTC Interim Report on PBMs, 2023).

The 2023 FTC Privacy Settlement

GoodRx paid $1.5 million to settle FTC charges that it shared sensitive prescription data with Facebook, Google, and Criteo without adequate user consent. The FTC charged the company under the Health Breach Notification Rule (FTC v. GoodRx Holdings, Feb 2023). Patients with HIV medications, mental health prescriptions, or hormone therapies in their GoodRx history had that data exposed to ad platforms. This is a concrete harm, not a hypothetical.

Patient Profile 1: Medicare Part D Enrollees

Medicare Part D enrollees should not use GoodRx as a substitute for running prescriptions through their Part D plan. This is the most clinically important warning in this article.

Why Part D and GoodRx Conflict

When a Part D enrollee uses a GoodRx discount instead of their insurance, the payment does not count toward the plan's true-out-of-pocket (TrOOP) threshold. The Centers for Medicare and Medicaid Services (CMS) defines TrOOP spending as payments made by the enrollee or certain approved sources through the Part D plan (CMS Medicare Prescription Drug Benefit Manual, Chapter 5). Cash paid via a discount card explicitly does not qualify.

The Catastrophic Coverage Gap Trap

A patient with high medication costs who bypasses Part D for several months may find they never reach the catastrophic coverage threshold where cost-sharing drops to 5%. In 2024, the catastrophic threshold is $8,000 in TrOOP spending. A patient who paid $600 out of pocket via GoodRx over six months accumulated zero TrOOP credit. The American Society of Consultant Pharmacists and the Medicare Rights Center have both published consumer advisories on this specific issue.

When Medicare Patients Might Still Use GoodRx

One narrow exception exists: a medication not covered on the patient's Part D formulary. In that case, GoodRx cash pricing may be the only affordable option, and no TrOOP credit would have accrued anyway. Patients should verify formulary exclusion through CMS Plan Finder before deciding.

Patient Profile 2: Patients on Specialty Biologics and Brand-Name Medications

GoodRx savings on brand-name biologics are often negligible or zero. Patients managing conditions like rheumatoid arthritis, multiple sclerosis, Crohn's disease, or plaque psoriasis with biologics such as adalimumab (Humira), ustekinumab (Stelara), or natalizumab (Tysabri) will find GoodRx cash prices in the range of $4,000 to $7,000 per month, occasionally with a 5 to 15% discount off retail. That is not meaningful savings.

What the Data Show on Specialty Drug Pricing

The Kaiser Family Foundation analyzed out-of-pocket costs for specialty drugs and found that patients with commercial insurance and manufacturer copay assistance paid a median of $0 to $50 per month for many biologics (KFF, Prescription Drug Cost Sharing, 2022). GoodRx cash pricing for the same drugs ran 80 to 100 times higher.

Manufacturer Patient Assistance Programs Are Superior

AbbVie's myAbbVie Assist, Janssen CarePath, and Novartis Patient Assistance Now each offer $0 or near-zero copay programs for qualifying patients. Eligibility typically requires income below 400% of the federal poverty level and no Medicare/Medicaid coverage. Patients should contact manufacturers directly or use the NeedyMeds database (NeedyMeds) rather than relying on GoodRx for specialty medications.

The National Alliance on Mental Illness states in its medication cost guide: "Manufacturer patient assistance programs routinely outperform third-party discount cards for brand-name and biologic medications, sometimes by thousands of dollars annually." (NAMI Medication Cost Resources)

Patient Profile 3: Patients with Active Commercial Insurance and a Low Deductible

A patient on an employer-sponsored plan with a $500 deductible and a $30 generic copay tier should not swap to GoodRx. The reason is simple: insurance spending counts toward both deductible and out-of-pocket maximum; GoodRx spending does not.

The Deductible Credit Problem

If a patient pays $18 for metformin via GoodRx instead of $30 through insurance, they save $12 now but lose $30 of deductible credit. Later in the year, when they need a $400 MRI or a branded medication, they will hit their deductible $30 later than they otherwise would have. For patients who reliably reach their deductible or out-of-pocket maximum each year, the net cost of using GoodRx on cheap generics is positive, meaning it costs them money in aggregate.

When GoodRx Beats Insurance Copay

Research published in JAMA Internal Medicine found that for 23% of the most commonly dispensed generic drugs, the GoodRx cash price was lower than the insurance copay at the point of sale (Kanter GP et al., JAMA Intern Med, 2018). For patients who are highly unlikely to meet their deductible in a given year, buying those specific generics via GoodRx is rational. The decision requires a calculation, not a default.

Patient Profile 4: Patients on Medicaid

Federal anti-kickback rules prohibit dual billing. A Medicaid beneficiary cannot use GoodRx and Medicaid for the same prescription at the same time. In most states, Medicaid copays for generics are $0 to $3. GoodRx would almost never beat that price. Using GoodRx instead of Medicaid for a covered drug produces no benefit and forfeits the Medicaid track record of the medication, which matters for prior authorization histories.

Patients should also be aware that some pharmacists have incorrectly billed Medicaid after a patient presented a GoodRx card, constituting a compliance violation. The HHS Office of Inspector General has investigated similar dual-billing schemes in pharmacy audits (HHS OIG Work Plan, Pharmacy Billing).

Patient Profile 5: Patients Who Value Data Privacy for Sensitive Medications

The 2023 FTC settlement established that GoodRx shared prescription histories with advertising platforms. For patients filling prescriptions for HIV antiretrovirals, psychiatric medications, controlled substances, or hormone therapies, this is not a trivial concern.

What Data Was Shared and With Whom

The FTC complaint specified that GoodRx transmitted data to Facebook's pixel, Google's advertising platform, and Criteo. The data included medication names, conditions implied by those medications, and device identifiers linking the information to specific individuals (FTC Complaint, GoodRx Holdings, 2023). The FTC stated: "GoodRx promised personal health information would not be shared with advertisers. GoodRx broke that promise."

HIPAA Does Not Fully Apply Here

GoodRx is not a covered entity or business associate under HIPAA in the same way a physician's office or pharmacy is. The FTC acted under its own Health Breach Notification Rule, not HIPAA enforcement. Patients who assume HIPAA protects their GoodRx data are operating under a misconception. The HHS Office for Civil Rights administers HIPAA and its scope is explained at HHS.gov HIPAA for Individuals.

Patient Profile 6: Patients in States with Pharmacy Board Restrictions or 340B Facilities Nearby

Several states have enacted regulations affecting how discount cards interact with state pharmacy programs. Patients who receive care at federally qualified health centers (FQHCs) or 340B-covered hospitals should fill prescriptions on-site. The 340B Drug Pricing Program mandates that covered entities purchase outpatient drugs at a statutory ceiling price, often 20 to 50% below wholesale acquisition cost (HRSA 340B Program Overview).

340B Prices Routinely Beat GoodRx

A 2020 analysis in the American Journal of Health-System Pharmacy found that 340B contract pharmacy prices were lower than GoodRx prices for 67 of 100 commonly prescribed generics studied (Am J Health-Syst Pharm, 2020). Patients who qualify for 340B dispensing (those treated at covered entities) should use that channel first.

State Pharmacy Assistance Programs

States including Pennsylvania (PACE/PACENET), New Jersey (PAAD), and New York (EPIC) operate their own pharmaceutical assistance programs for seniors and low-income residents. These programs set co-pays as low as $6 per prescription. The National Council on Aging maintains a searchable directory (NCOA BenefitsCheckUp).

GoodRx Complaints: What the BBB and Consumer Data Show

GoodRx holds BBB accreditation but carries a 1.44 out of 5 customer review score based on over 200 reviews as of early 2024. Complaint themes cluster into four categories.

Category 1: Insurance Claim Interference

The most common complaint: a pharmacy technician ran GoodRx alongside insurance, resulting in a claim rejection or a balance bill. Patients should confirm with the pharmacist that GoodRx is being used in place of insurance, not layered on top.

Category 2: Advertised Price Not Available at Pharmacy

GoodRx prices are estimates based on contracted rates. Individual pharmacy systems may not honor the displayed price if their PBM adjudication returns a different figure. A 2019 study in Annals of Internal Medicine found that GoodRx prices shown online differed from actual dispensing prices at the pharmacy counter in a meaningful proportion of transactions (Sarpatwari A et al., Ann Intern Med, 2019). The price shown is a ceiling estimate, not a guarantee.

Category 3: Data and Account Issues

Following the FTC settlement, users reported difficulty deleting accounts and revoking data-sharing consents. GoodRx updated its privacy tools post-settlement, but patients should review the current privacy center at goodrx.com/privacy before entering sensitive prescription data.

Category 4: GoodRx Gold Subscription Cancellation

GoodRx Gold is a paid subscription ($9.99/month for individuals). Complaints on the BBB and Trustpilot involve difficulty canceling recurring charges. Patients should treat the subscription as any other recurring billing and document the cancellation date.

A Framework for Deciding Whether GoodRx Is Right for You

The following decision logic covers the most common clinical scenarios. It is not a substitute for personalized advice from a pharmacist or prescriber.

Step 1. Are you enrolled in Medicare Part D? If yes, check your formulary first. Use GoodRx only for drugs completely absent from your formulary, and confirm with your Part D plan.

Step 2. Do you have commercial insurance with a realistic chance of meeting your deductible this year? If yes, run most prescriptions through insurance to accumulate credit.

Step 3. Is the medication a specialty biologic priced above $1,000/month? If yes, contact the manufacturer's patient assistance program before using GoodRx.

Step 4. Do you receive care at a federally qualified health center or 340B hospital? If yes, fill prescriptions on-site through the 340B channel.

Step 5. Are you uninsured or underinsured and buying a common generic (metformin, lisinopril, levothyroxine, amlodipine, atorvastatin)? GoodRx pricing is likely competitive and appropriate.

What Clinical Guidelines Say About Prescription Affordability Tools

The American Diabetes Association 2024 Standards of Care state: "For patients who are cost-constrained, clinicians should assist in identifying lower-cost insulin options, manufacturer savings cards, and pharmacy discount programs where appropriate, recognizing that each patient's insurance status and cost-sharing structure determines which tool produces the greatest savings." (ADA Standards of Care 2024, Section 6)

The American Heart Association's 2023 science advisory on medication adherence noted that cost-related non-adherence affects approximately 29% of adults prescribed cardiovascular medications and that discount programs vary widely in effectiveness depending on plan design (AHA Science Advisory, Medication Adherence, 2023).

A 2021 Cochrane review on interventions to improve adherence to lipid-lowering drugs found that cost reduction interventions improve adherence modestly (risk ratio 1.33, 95% CI 1.17 to 1.52) but that the effect size depends heavily on the magnitude of the cost reduction achieved (Cochrane: Interventions for Adherence, Lipid-Lowering, 2021).

Safer Alternatives by Patient Type

Different patients need different solutions. A quick reference:

| Patient Type | Recommended Alternative | Where to Apply | |---|---|---| | Medicare Part D enrolled | Part D formulary drug | medicare.gov/plan-compare | | Medicaid enrolled | State Medicaid pharmacy benefit | State Medicaid office | | Specialty biologic patient | Manufacturer PAP or copay card | Manufacturer website | | 340B-eligible patient | 340B dispensing site | HRSA 340B database | | Low-income uninsured | NeedyMeds, RxAssist, state PAP | needymeds.org | | Commercial insured (will meet deductible) | Insurance copay | Your pharmacy | | Uninsured, generic medication | GoodRx, Blink Health, Cost Plus Drugs | Comparison shop |

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) offers transparent manufacturer-plus-15% pricing on over 2,500 generics with no membership fee, and for many medications its prices match or undercut GoodRx (Cost Plus Drugs Pricing Model, NEJM Catalyst, 2023).